As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Sagimet Biosciences Inc. The largest reported stake is BlackRock, Inc.'s, at 7.8%. 7 filings are on record since August 14, 2025 (Schedule 13G, July 30, 2026).
Sell to companies like Sagimet Biosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Commodore Capital LP · Sole voting: 0 · Shared voting: 5,507,752 · Sole dispositive: 0 · Shared dispositive: 5,507,752 · SCHEDULE 13G, 2026-10-07
- · Reporting person: Balyasny Asset Management L.P. · Sole voting: 3,626,113 · Shared voting: 0 · Sole dispositive: 3,626,113 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 4,690,270 · Shared voting: 0 · Sole dispositive: 4,751,186 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-30
- · Holder: KPCB Pandemic and Bio Defense Fund, LLC · Percent: 0% · Shares: 0 · SCHEDULE 13G/A
- · Holder: Woodline Partners LP · Percent: 4.8% · SCHEDULE 13G/A
Sagimet Biosciences Inc. has 7 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of series a common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 7.8% | 4,751,186 | SCHEDULE 13G, 2026-07-30 | 2026-06-30 |
| Commodore Capital LP | 7.6% | 5,507,752 | SCHEDULE 13G, 2026-10-07 | 2026-09-30 |
| Balyasny Asset Management L.P. | 5.93% | 3,626,113 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Woodline Partners LP | 4.8% | 1,501,357 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Point72 Asset Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| KPCB Pandemic and Bio Defense Fund, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-12-18 | 2025-12-18 |
Holding shares or following this stake? See who's behind Sagimet Biosciences Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Sagimet Biosciences Inc. and the records around it.
Sagimet Biosciences Inc. elsewhere on the record
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- BALYASNY ASSET MANAGEMENT L.P. also filed stake reports on 31 other companies: Beyond Air, Inc. (Aug 2026), Camp4 Therapeutics Corp. (Aug 2026), CELLECTAR BIOSCIENCES, INC. (Aug 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026), InflaRx N.V. (Aug 2026)
Watch Sagimet Biosciences Inc.
Get an email when Sagimet Biosciences Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sagimet Biosciences Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sagimet Biosciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sagimet Biosciences Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,690,270 | 0 | 4,751,186 | 0 | SCHEDULE 13G, 2026-07-30 |
| Commodore Capital LP | 0 | 5,507,752 | 0 | 5,507,752 | SCHEDULE 13G, 2026-10-07 |
| Commodore Capital Master LP | 0 | 5,507,752 | 0 | 5,507,752 | SCHEDULE 13G, 2026-10-07 |
| Robert Egen Atkinson | 0 | 5,507,752 | 0 | 5,507,752 | SCHEDULE 13G, 2026-10-07 |
| Michael Kramarz | 0 | 5,507,752 | 0 | 5,507,752 | SCHEDULE 13G, 2026-10-07 |
| Balyasny Asset Management L.P. | 3,626,113 | 0 | 3,626,113 | 0 | SCHEDULE 13G, 2026-08-14 |
| Bam Gp LLC | 3,626,113 | 0 | 3,626,113 | 0 | SCHEDULE 13G, 2026-08-14 |
| Balyasny Asset Management Holdings LP | 3,626,113 | 0 | 3,626,113 | 0 | SCHEDULE 13G, 2026-08-14 |
| Dames GP LLC | 3,626,113 | 0 | 3,626,113 | 0 | SCHEDULE 13G, 2026-08-14 |
| Dmitry Balyasny | 3,626,113 | 0 | 3,626,113 | 0 | SCHEDULE 13G, 2026-08-14 |
| KPCB Pandemic and Bio Defense Fund, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-12-18 |
| KPCB PBD Associates, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-12-18 |
The latest filing identifies Sagimet Biosciences Inc. by CUSIP 786700104 and gives its principal executive office as 950 Tower Lane, Suite 1500, Foster City, CA 94404 (SCHEDULE 13G, 2026-10-07).
What the percentages are based on
Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 5.93% of the Shares, based on 61,184,313 Shares of common stock outstanding as of May 5, 2026 as reported in the Issuer's Form 10-Q as filed with the Securities Exchange Commision on May 12, 2026.Balyasny Asset Management L.P., SCHEDULE 13G, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Woodline Partners LP | 8.3% | SCHEDULE 13G |
| 2025-08-14 | Point72 Asset Management, L.P. | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Woodline Partners LP | 4.8% | SCHEDULE 13G/A |
| 2025-12-18 | KPCB Pandemic and Bio Defense Fund, LLC | 0% | SCHEDULE 13G/A |
| 2026-07-30 | BlackRock, Inc. | 7.8% | SCHEDULE 13G |
| 2026-08-14 | Balyasny Asset Management L.P. | 5.93% | SCHEDULE 13G |
| 2026-10-07 | Commodore Capital LP | 7.6% | SCHEDULE 13G |
Questions about who owns Sagimet Biosciences Inc.
Who owns Sagimet Biosciences Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Sagimet Biosciences Inc.: BlackRock, Inc. (7.8%, Schedule 13G, filed 2026-07-30), Commodore Capital LP (7.6%, Schedule 13G, filed 2026-10-07) and Balyasny Asset Management L.P. (5.93%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Sagimet Biosciences Inc.?
By the share each holder's latest filing reports, the largest holders of Sagimet Biosciences Inc. on this page are BlackRock, Inc. (7.8%), Commodore Capital LP (7.6%) and Balyasny Asset Management L.P. (5.93%).
When did BlackRock, Inc. buy into Sagimet Biosciences Inc.?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G, filed 2026-07-30, reporting 7.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Sagimet Biosciences Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.